Prophase Labs (PRPH) Q3 2025 Earnings Report

335 Followers

Previous Report: Q2 2025

Next Report: Q4 2025

PRPH Q3 2025 EPS Results

Actual EPS-$1.60

Consensus EPS―

Beat/Miss―

One Year Ago EPS-$3.50

PRPH Q3 2025 Revenue Results

Actual Revenue$883.00K

Expected Revenue―

Beat/Miss―

YoY Revenue Growth-71.93%

Earnings Announcement Details

QuarterQ3 2025

Date11/19/2025

TimeBefore Open

Conference CallWednesday, November 19, 2025

PRPH Upcoming Earnings

Prophase Labs's next earnings date is estimated for November 5, 2026, based on past reporting schedules.

Q3 2025 Earnings Call Audio

PRPH Q3 2025 Earnings Call

0:00 / 0:00

Q3 2025 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2025 Earnings Call Summary

Q3 2025

Earnings Call Date:Nov 19, 2025|

% Change Since:

Earnings Call Sentiment|Neutral

The earnings call highlighted several promising developments, such as the Crown Medical collections, potential partnerships for the esophageal cancer test, and a turnaround in the Nebula Genomics business. However, these positives were counterbalanced by significant challenges, including financial constraints, a declining stock price, and the need for a reverse stock split to maintain Nasdaq compliance. The company is actively pursuing strategic initiatives to address these issues and improve shareholder value.

Company Guidance

During the ProPhase Labs, Inc.'s third-quarter 2025 earnings call, Chairman and CEO Ted Karkus provided several metrics and strategic insights. He emphasized the importance of shareholder voting on a critical proxy, which could impact strategic initiatives. The company is targeting collections of around $150 million in uncollected COVID testing claims, with expectations to net at least $50 million after discounts and fees. Karkus also discussed the potential of the BSmart esophageal cancer test, estimating a target market of $7-14 billion, and highlighted Nebula Genomics' restructuring towards profitability. ProPhase Labs' current market cap stands at approximately $12 million, with 46.1 million shares outstanding. Karkus addressed the possibility of a reverse stock split to maintain Nasdaq compliance, aiming to capitalize on the company's undervalued stock and significant asset potential.

Crown Medical Collections Initiative

Crown Medical has been appointed special counsel to collect $150 million in uncollected COVID testing claims. They expect to collect at least $50 million net, which could significantly improve the company's financial situation.

B Smart Esophageal Cancer Test

The esophageal cancer test is considered one of the best diagnostic tests for one of the deadliest cancers. Now that it's been published in a major journal, it has attracted interest from various companies looking to partner or acquire.

Nebula Genomics Business Turnaround

The Nebula Genomics business has been restructured to become primarily direct-to-consumer, with a subscription model that is profitable on a pro forma basis.

Potential Strategic Initiatives

The company is exploring multiple strategic initiatives, including potential M&A deals and partnerships, which could significantly enhance shareholder value. They are also considering a crypto treasury strategy once cash flow improves.

PRPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 05, 2026	2026 (Q3)	- / -	-0.16	―
Aug 06, 2026	2026 (Q2)	- / -0.22	-1.1	80.18% (+0.88)
May 07, 2026	2026 (Q1)	- / -	-0.13	―
Apr 15, 2026	2025 (Q4)	- / -0.42	-1.3	67.69% (+0.88)
Nov 19, 2025	2025 (Q3)	- / -1.60	-3.5	54.29% (+1.90)
Aug 13, 2025	2025 (Q2)	-1.50 / -1.10	-3.3	66.67% (+2.20)
May 20, 2025	2025 (Q1)	- / -0.13	-0.7	81.43% (+0.57)
Mar 31, 2025	2024 (Q4)	-1.80 / -1.30	-0.7	-85.71% (-0.60)
Nov 13, 2024	2024 (Q3)	-3.10 / -3.50	-3	-16.67% (-0.50)
Aug 14, 2024	2024 (Q2)	-0.80 / -3.30	-2	-65.00% (-1.30)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed